Guggenheim Maintains Buy on Eli Lilly (LLY) After “Another Impressive Year”

On December 3, Guggenheim raised its terms people connected Eli Lilly and Company (NYSE:LLY) to $1,163 from $1,036 and kept a Buy standing connected the stock. The steadfast updated its models for LLY based connected medicine trends and GLP-1 pricing news. While highlighting that the institution “delivered different awesome twelvemonth of banal show successful 2025,” the steadfast “simply cannot reason with the company’s superior wide execution capitalizing afloat connected the Pharma mega rhythm of our lifetime,” the expert tells investors.

Eli Lilly and Company (NYSE:LLY) has performed exceptionally good implicit the past fewer years, gaining implicit 580% successful the past 5 years. One of the reasons for this maturation is the company’s strengths successful the value nonaccomplishment cause market. Its imaginable value nonaccomplishment pill, orforglipron, could beryllium the company’s caller maturation driver. In its caller net news, LLY declared that orforglipron showed encouraging results successful late-stage trials. The institution besides plans to question regulatory support for its usage successful obesity earlier the twelvemonth ends.

Overall, Eli Lilly and Company (NYSE:LLY) delivered gross of $17.6 cardinal successful the 3rd 4th of 2025, which showed a staggering maturation of 53.8% from the aforesaid play past year. The gross surpassed analysts’ estimates by $1.53 billion. The gross maturation drivers were chiefly Mounjaro and Zepbound. These drugs besides performed remarkably well, with Mounjaro’s worldwide gross surging by 10% and Zepbound’s by 184%.

Eli Lilly and Company (NYSE:LLY) is an American multinational pharmaceutical institution that discovers and markets a wide scope of pharmaceuticals.

While we admit the imaginable of LLY arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you’re looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 15 Blue Chip Dividend Stocks to Build a Passive Income Portfolio and 15 Dividend Stocks That Outperform the S&P 500.

Disclosure: None.